The role of protein traffic in the progression of renal diseases

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 315-327

  Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Clinical trials; Inflammatory mediators; Proteinuria; Tubulointerstitial injury

Indexed keywords

CAPILLARY PRESSURE; DISEASE COURSE; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; NEPHRON; PRIORITY JOURNAL; PROTEIN TRANSPORT; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; URINARY EXCRETION;

ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNOPHENOTYPING; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; PROTEINS; PROTEINURIA; UROTHELIUM;

EID: 0034048667     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.315     Document Type: Review

References (60)

1. 1. Brenner BM, Meyer TW, Hostetter TH. 1982. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307:652-59
2. 2. Bright R. 1827. Reports of Medical Cases, Selected with a View of Illustrating the Symptoms and Cure of Diseases by a Reference to Morbid Anatomy. London: Longman, Rees, Orme, Brown & Green
3. 3. Addis T, Oliver J. 1931. The Renal Lesion in Bright's Disease. New York: Paul Hoeber
4. 4. Addis T. 1940. The osmotic work of the kidney and the treatment of glomerular nephritis. Trans. Assoc. Am. Phys. 55: 223-29
5. 5. Volhard F, Fahr TH. 1914. Die Bright' sche Nierenkrankheit, Table II. Berlin: Julius Springer
6. 6. Mollendorf W, Stohr P. 1924.Lehrbuch der Histologie. Jena, Germany: Fischer. 343 pp.
7. 7. Allen AC. 1951. The Kidney, Medical and Surgical Diseases. New York: Grune & Stratton. 207 pp.
8. 8. Oliver J, MacDowell M, Lee YC. 1954. Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria, tubular absorption, droplet formation, and the disposal of proteins. J. Exp. Med. 99:589-604
9. 9. Cameron JS, Turner DS, Ogg GS, et al. 1978. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin. Nephrol. 10:213-18
10. 10. Cameron JS, Turner DS, Ogg GS, et al. 1978. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin. Nephrol. 10:213-18
11. 11. Row PG, Cameron JS, Turner DR, et al. 1975. Membranous nephropathy: long-term follow up and association with neoplasia. Q. J. Med. 44:207
12. 12. Habib R. 1973. Focal glomerular sclerosis. Kidney Int. 4:355
13. 13. Hostetter TH, Olson JL, Rennke HG, et al. 1981. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 241: F85-93
14. 14. Mogensen CE, Christensen CK, Beck-Nielsen H. 1983. Early changes in kidney function, blood pressure, and the stages in diabetic nephropathy. In Prevention and Treatment of Diabetic Nephropathy, ed. H Keen, M Legrain, pp. 57-83. Boston: MTP Press
15. 15. Parving HH, Andersen AR, Smidt UM, Svendsen PA. 1983. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-79
16. 16. Anderson S, Meyer TW, Rennke HG, Brenner BM. 1985. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 76:612-19
17. 17. Bohrer MP, Deen WM, Robertson CR, Brenner BM. 1977. Mechanism of angiotensin II induced proteinuria in the rat. Am. J. Physiol. 233:F13-21
18. 18. Mathiesen ER, Hommel E, Giese J, Parving H-H. 1991. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87
19. 19. Bertani T, Cutillo F, Zoja C, et al. 1986. Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int. 30:488-96
20. 20. Remuzzi G, Bertani T. 1990. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 38:384-94
21. 21. Eddy AA, Michael AF. 1988. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int. 33:14-23
22. 22. Remuzzi G, Ruggenenti P, Benigni A. 1997. Understanding the nature of renal disease progression. Kidney Int. 51:2-15
23. 23. Remuzzi G, Bertani T. 1998. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339:1448-56
24. 24. Zoja C, Morigi M, Figliuzzi M, et al. 1995. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 26:934-41
25. 25. Wang Y, Chen J, Chen L, et al. 1997. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J. Am. Soc. Nephrol. 8:1537-45
26. 26. Zoja C, Donadelli R, Colleoni S, et al. 1998. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int. 53:1608-15
27. 27. Bruzzi I, Corna D, Zoja C, et al. 1997. Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am. J. Pathol. 151: 1241-47
28. 28. Zoja C, Liu X-H, Abbate M, et al. 1998. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Exp. Nephrol. 6:121-31
29. 29. Eddy AA, Giachelli CM. 1995. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 47:1546-57
30. 30. Tang WW, Qi M, Warren JS, Van GY. 1997. Chemokine expression in experimental tubulointerstitial nephritis. J. Immunol. 159:870-76
31. 31. Lloyd CM, Minto AW, Dorff ME, et al. 1997. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185:1371-80
32. 32. Abbate M, Zoja C, Corna D, et al. 1998. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J. Am. Soc. Nephrol. 9:1213-24
33. 33. Kliem V, Johnson RJ, Alpers CE, et al. 1996. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/ 6-nephrectomized rats. Kidney Int. 49: 666-78
34. 34. Johnson DW, Saunders HJ, Baxter RC, et al. 1998. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 54:747-57
35. 35. Eddy A. 1996. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 7:2495-508
36. 36. Hostetter TH, Meyer TW, Rennke HG, Brenner BM. 1986. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 30: 509-17
37. 37. Wen S-F, Huang T-P, Moorthy AV. 1985. Effect of low-protein diet on experimental diabetic nephropathy in the rat. J. Lab. Clin. Med. 106:589-97
38. 38. Zoja C, Remuzzi A, Corna D, et al. 1992. Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. Am. J. Med. 92:60S-63S (Suppl.)
39. 39. Zatz R, Dunn BR, Meyer TW, et al. 1986. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77:1925-30
40. 40. Remuzzi A, Perico N, Amuchastegui CS, et al. 1993. Short-and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. Nephrol. 4:40-49
41. 41. Remuzzi A, Puntorieri S, Battaglia C, et al. 1990. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J. Clin. Invest. 85:541-49
42. 42. Zoja C, Corna D, Bruzzi I, et al. 1996. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp. Nephrol. 4:213-21
43. 43. Zoja C, Corna D, Benigni A, et al. 1998. The effect of lisinopril, mycophenolate mofetil (MMF) and their combination on renal disease progression in rats with remnant kidney (RMR). J. Am. Soc. Nephrol. 9:491A (Abstr.)
44. 44. Benigni A, Corna D, Maffi R, et al. 1998. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 54:353-59
45. 45. Breyer JA, Bain RP, Evans JK, et al. 1996. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int. 50:1651-58
46. 46. Peterson JC, Adler S, Burkart JM, et al. 1995. Blood pressure control, proteinuria, and the progression of renal disease. Ann. Intern. Med. 123:754-62
47. 47. Ruilope LM, Alcazar JM, Hernandex E, et al. 1990. Does an adequate control of blood pressure protect the kidney in essential hypertension? J. Hypertens. 8:525-31
48. 48. Ruggenenti P, Perna A, Mosconi L, et al. 1997. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int. 52:S54-57 (Suppl.)
49. 49. Rossing P, Hommel E, Smidt UM, Parving H. 1993. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-19
50. 50. Gall MA, Nielsen FS, Smidt UM, Parving HH. 1993. The course of kidney function in type-2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36:1071-78
51. 51. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. 1998. Cross-sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 316:504-9
52. 52. Walker JD, Bending JJ, Dodds RA, et al. 1989. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 2:1411-15
53. 53. El Nahas AM, Masters-Thomas A, Brady SA, et al. 1984. Selective effect of low protein diets in chronic renal diseases. BMJ 289:1337-4
54. 54. Bjorck S, Mulec H, Johnsen SA, et al. 1992. Renal protective effect of enalapril in diabetic nephropathy. BMJ 304:339-43
55. 55. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. 1993. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329: 1456-62
56. 56. Breyer JA. 1995. Medical management of nephropathy in type I diabetes mellitus: current recommendations. J. Am. Soc. Nephrol. 6:1523-29
57. 57. Maschio G, Alberti D, Janin G, et al. 1996. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334:939-45
58. 58. The Gisen Group. 1997. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-63
59. 59. Ruggenenti P, Perna A, Gherardi G, et al. 1998. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352:1252-56
60. 60. Ruggenenti P, Perna A, Benini R, et al. 1999. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J. Am. Soc. Nephrol 10:997-1006